Description

Cultrex®BasementMembraneExtract(BME)isasolubleformofbasementmembranepurifiedfromEngelbreth-Holm-Swarm(EHS)tumor.Thisextractprovidesanaturalextracellularmatrixhydrogelthatpolymerizesat37°Ctoformareconstitutedbasementmembrane.Basementmembranesarecontinuoussheetsofspecializedextracellularmatrixthatformaninterfacebetweenendothelial,epithelial,muscle,orneuronalcellsandtheiradjacentstromaandthatplayanessentialroleintissueorganizationbyinfluencingcelladhesion,migration,proliferation,anddifferentiation.ThemajorcomponentsofBMEincludelaminin,collagenIV,entactin,andheparansulfateproteoglycans.

Cultrex®BMEType3isphysiologicallyalignedwiththeinvivoenvironmentandisrecommendedforxenografts,tumorgrafts,andotherinvivoapplications.

Qualitycontrolspecifications:

• Mousecoloniesareroutinelyscreenedforpathogensusing mouseantibodyproduction(MAP)testing.
• Engelbreth-Holm-Swarm(EHS)tumorisLDEV-free.
• PathClear®–testednegativebyPCRfor 17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.
• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
• Endotoxinconcentration≤8EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
• Proteinconcentrationof12–18mg/ml.
• NomycoplasmacontaminationdetectedbyPCR.
• ProvidedinRoswellParkMemorialInstituted(RPMI) mediumwith10µg/mlgentamycin.
• GelstABIlitytestedforaperiodof14daysat37°C.
• BIOLOGicalactivitydeterminedforeachlot:
  • TumorGrowthAssay–BMEType3supportsproliferationandgrowthofbreastcancercells(MCF7)embeddedinthematrixforminimumof8days.

Catalog#3632-010-02includes:
CatalogNumber	Description	Qty
3632-005-02	Cultrex®BasementMembraneExtract,Type3,PathClear®	2

GeneticIdentificationofSEMA3FasanAntilymphangiogenicMetastasisSuppressorGeneinHeadandNeckSquamousCarcinoma
ColleenL.Doçi,ConstantinosM.Mikelis,MichailS.Lionakis,AlfredoA.Molinolo,andJ.SilvioGutkind
CancerRes.,Jul2015;75:2937–2948.
http://cancerres.aacrjournals.org/cgi/content/abstract/75/14/2937

Trevigen公司位于美国马里兰州的高科技走廊，是一家有12年历史、成长迅速的生物技术公司，其产品和技术的发展方向主要在癌症研究领域，重点强调细胞凋亡、DNA损伤和修复，以及癌症细胞功能和行为。Trevigen品牌的分销商遍及北美，欧洲和环太平洋地区。关于DNA的损伤分析技术的研究，Trevigen获得美国国立卫生研究院（NIH）的SBIR项目资助。